«ТЫГЫЗДАЛГАН» АДЪЮВАНТТУУ ХИМИОТЕРАПИЯ – ЭМЧЕК БЕЗДЕРИНИН РАК ООРУСУН ДАРЫЛООНУН ЖАҢЫ СТРАТЕГИЯСЫ
Аннотация
Бул изилдөө ишинде эмчек безинин рак оорусу менен ооруган оорулууларды дарылоодо колдонулган адъюванттык химиотерапиянын («тыгыздалган» химиотерапия 2 режимде, жанаистандарттуу) 3 методуна салыштыруу жүргүзүлдү.
Ключові слова:
эмчек безинин ракы, «тыгыздалган» химиотерапия, адъюванттуу химиотерапия.Посилання
1. Bonnadona G, Valagussa P, Moliterni P. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20-years of follow-up. New Engl J Med 1995;332: 901-906.
2. Hamilton A and Hortobagyi G. Chemotherapy: What progress in the last 5 years. J ClinOncol 2005; 23: 1760-1775.
3. Piccart-Gebhart M. Mathematics and Oncology: A Match for Life? J ClinOncol 2003; 21: 1425-1428.
4. Blume KG. Thomas ED. A review of autologous hematopoeitic cell transplantation. Biol Blood Marrow Transplant 2000, 6: 1-12.
5. Gutierrez-Delgado F, Maloney DG, Press OW, et al. Autologous stem cell transplantation for non-Hodgkin lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant 2001; 28: 455-61.
6. Gutierrez-Delgado F, Maloney DG, Holmberg LA, et al. Autologous stem cell transplantation for patients with Hodgkin’s disease, a comparison of two high-dose chemotherapy regimens. Bone Marrow Transplant 2003, 32:279-85.
7. Gutierrez-Delgado F, Holmberg LA, Hooper H, et al. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer. Bone Marrow Transplant 2000; 26:51-59.
8. Hrnyuk WM, Bush H. The important of dose intensity in chemotherapy of metastatic breast cancer. J ClinOncol 1984; 2: 1281-1288.
9. Budman DR, Berry DA, Cirrincione CT. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer: The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90: 1205-1211.
10. Gutierrez-Delgado F, Titov D, Tjulandin SA and Garin AM. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin (BEP) combination chemotherapy for nonseminomatous germ cell tumor patients. Neoplasma. 1999; 46:190-5.
11. Norton L. Conceptual and Practical implications of breast tissue geometry: Toward a more effective, less toxic therapy. The Oncologist 2005; 10: 370-381.
12. Skipper HE, Schabel FM, Wilcox X. Experimental evaluation of potential anticancer agents. XIII: On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother Rep 1964; 35: 1-111.
13. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971; 28: 1479-1499.
14. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163-169.
15. Norton L, Simon R, Brereton J, et al. Predicting the course of Gompertzian growth. Nature; 1976: 542-555.
16. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-1733.
17. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273: 542-547.
18. Bonadonna G, Zambetti M, MoliterniA et al. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate and fluorouracil in operable breast cancer. J ClinOncol 2004; 22: 1614-1620.
19. Citron ML, Berry DA, Cirincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J ClinOncol 2003; 21: 1431-1439.
